Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
Interventions
DRUG

Biphasic Remogliflozin Etabonate

Experimental Drug

OTHER

Placebo

Placebo Comparator

Trial Locations (19)

29651

Mountain View Clinical Research, Greer

32127

Progressive Medical Research, Port Orange

33012

Medical Research Unlimited, Hialeah

33634

Meridien Research, Tampa

37909

New Phase Research & Development, Knoxville

77074

Juno Research, LLC, Houston

78404

Padre Coast Clinical Research, Corpus Christi

78756

Austin Center for Clinical Research, Austin

84107

Wasatch Clinical Research, Salt Lake City

85712

Advanced Arizona Clinical Research, Tucson

87102

Albuquerque Clinical Trials, Inc, Albuquerque

89109

eStudySite, Las Vegas, Las Vegas

90057

National Research Institute, Los Angeles

90806

Long Beach Clinical Trials, Long Beach

90807

Long Beach Center for Clinical Research, Long Beach

92780

Orange County Research Center, Tustin

94598

Diablo Clinical Research, Walnut Creek

06708

Chase Medical Research, Waterbury

08009

Comprehensive Clinical Research, Berlin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

BHV Pharma

INDUSTRY